Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kymera Therapeutics, Inc. - Common Stock
(NQ:
KYMR
)
100.33
-3.07 (-2.97%)
Streaming Delayed Price
Updated: 3:00 PM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kymera Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
June 25, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 07, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
July 31, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
July 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
July 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
May 29, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 23, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
May 22, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 14, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
May 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
May 02, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
April 25, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
April 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
March 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
February 28, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
February 22, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
February 15, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
January 31, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
January 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
January 05, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Proposed Public Offering
January 04, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
January 04, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
January 02, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
December 13, 2023
Company to provide update on its emerging pipeline of high-value immunology programs
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
December 10, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
